|

Bimekizumab Clinical Trials

4 actively recruiting trials across 2 locations

Also known as: BKZ, Bimzelx®, N/A (Not applicable)

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • UCB Biopharma SRL3
  • NHS Greater Glasgow and Clyde1

Indications

  • Arthritis4
  • Psoriatic Arthritis3
  • Moderate to Severe Plaque Psoriasis2
  • Enthesitis Related Arthritis1
  • Juvenile Psoriatic Arthritis1

Other2 trials

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Phase 3
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Birmingham, Alabama1 trial

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Ps0039 50140

Phase 3

Santa Monica, California1 trial

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Up0122 105

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.